Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.43 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.42 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022337 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4HSD17B1HSD17B2FDFT1 | |
| Cadaverine Tartrate SCHEMBL1023377 | 0.89 | CHRNB2 (0.43) | CHRNB2CHRNA4HSD17B1HSD17B2P2RY14 | |
| Cadaverine Tartrate SCHEMBL1023378 | 0.89 | CHRNB2 (0.43) | CHRNB2CHRNA4HSD17B1HSD17B2P2RY14 | |
| SCHEMBL7805901 | 0.87 | CHRNB2 (0.54) | CHRNB2CHRNA4P2RY14CCNT1CDK9 | |
| SCHEMBL1023489 | 0.83 | CHRNB2 (0.54) | CHRNB2CHRNA4P2RY14CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL1025419 | 0.82 | CHRNB2 (0.52) | CHRNB2CHRNA4P2RY14CCNT1CDK9 | |
| SCHEMBL1023383 | 0.81 | CHRNB2 (0.48) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL1023384 | 0.81 | CHRNB2 (0.48) | CHRNB2CHRNA4P2RY14 | |
| Hydrochloric Acid SCHEMBL1072684 | 0.80 | CHRNB2 (0.47) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL2417457 | 0.79 | CHRNB2 (0.42) | CHRNB2CHRNA4CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272847-A1 | Enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors | NeuroSearch A/S (DK) | 2011-01-12 | — | — | EP | claimed |
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2009-05-28 | — | — | US | claimed |
| EP-1869033-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-12-26 | — | — | EP | claimed |
| WO-2006108789-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | claimed |
| EP-2272847-A1 | Enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors | NeuroSearch A/S (DK) | 2011-01-12 | — | — | EP | disclosed |
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| EP-1869033-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108789-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
| EP-1390364-B1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1390364-A1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | Wyeth (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6632824-B2 | Have the ability to act at the 5-HT transporter. | WYETH | 2003-10-14 | — | — | US | disclosed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2002096906-A1 | ARYL-8-AZABICYCLO[3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | HTR1A, HTR1D, HTR2C | CHRNB2 79/4885CHRNA4 63/4885HSD17B1 186/4885 |
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | CHRNB2 90/4885CHRNA4 129/4885HSD17B1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.